AUTHORS
Claudia Bruedigam, PhD, Adithi Kamana2, Chu-Han Huang3, Eunice Anne Dulatre4, Katherine J. Jeppe5, Christopher K. Barlow6, Natasha Kapoor-Kaushik7, Tasha S.C. Lumbantobing8, Joel R. Steele9, Han-Chung Lee10, Krisha Sidhu11, Dominic Cerny12, Georg Ramm13, Ralf B. Schittenhelm14, Tina M. Schnoeder15, David J Curtis, PhD, MBBS16, Florian H. Heidel IV, MD17, Steven W. Lane, MD, PhD18
AFFILIATIONS
1 Monash University, Melbourne, Victoria, Australia
2 Monash University, Melbourne, Victoria, Australia
3 Monash University, Melbourne, Victoria, Australia
4 Monash University, Melbourne, Victoria, Australia
5 Monash University, Melbourne, Victoria, Australia
6 Monash University, Melbourne, Victoria, Australia
7 Monash University, Melbourne, Victoria, Australia
8 Monash University, Melbourne, Victoria, Australia
9 Monash University, Melbourne, Victoria, Australia
10 Monash University, Melbourne, Victoria, Australia
11 Monash University, Melbourne, Victoria, Australia
12 Monash University, Melbourne, Victoria, Australia
13 Monash University, Melbourne, Victoria, Australia
14 Monash University, Melbourne, Victoria, Australia
15 Hannover Medical School (MHH), Hannover, Germany
16 Monash University, Melbourne, Victoria, Australia
17 Hannover Medical School (MHH), Hannover, Germany
18 QIMR Berghofer, Brisbane, Australia, Royal Brisbane and Women’s Hospital, Brisbane, Australia, The University of Queensland, Brisbane, Australia
ABSTRACT
Imetelstat is a first-in-class lipid-conjugated 13-mer thiophosphoramidate oligonucleotide that competitively inhibits telomerase. Recently approved by the US Food and Drug Administration and European Commission for selected adults with transfusion-dependent lower-risk myelodysplastic syndromes, imetelstat is in clinical development for acute myeloid leukaemia (AML). We previously showed that imetelstat increases polyunsaturated fatty acid (PUFA)-containing phospholipids, lipid ROS and ferroptosis in AML stem cells. Inhibition of lysosomal acidification prevents imetelstat-induced lipid peroxidation and AML cell death. Here, we investigated whether lysosomal acidification is required for imetelstat-induced lipid changes associated with ferroptosis and whether imetelstat treatment exposes targetable metabolic dependencies in AML.
NB4 cells were treated for 19-21 hours with vehicle, imetelstat (4 μM), bafilomycin A1 (2 nM), or both. Four independent experiments using different cell passages generated 4 biological replicates per condition. Each replicate was divided into matched aliquots for untargeted lipidomic, proteomic and metabolomic analyses. Among 720 quality-controlled lipid features, we identified an imetelstat-enriched lipid signature that was absent when bafilomycin was present. This signature included highly unsaturated phosphatidylcholines (PCs), phosphatidylethanolamines and triglycerides, as well as sphingomyelins and coenzyme Q10. The median increases were 1.78-fold for highly unsaturated PCs and 2.10-fold for highly unsaturated triglycerides. In separate experiments, transmission electron microscopy showed that imetelstat altered lipid-droplet morphology and increased electron density within lipid-droplet cores, while bafilomycin prevented these changes. These data show that intact lysosomal acidification is required for the acute PUFA-rich phospholipid and neutral-lipid changes induced by imetelstat.
Proteomics identified 7,120 proteins at a false-discovery rate below 1%. After multiple-testing correction, imetelstat increased squalene epoxidase (SQLE) 6.30-fold (adjusted p = 0.040) and squalene synthase (FDFT1) 2.05-fold (adjusted p = 0.049), while reducing SPTBN2 to 0.37-fold relative to vehicle (adjusted p = 0.049). Bafilomycin restored SPTBN2 to vehicle levels (imetelstat versus combination, adjusted p = 0.015), but did not prevent the increases in SQLE or FDFT1. We next analysed a fixed 12-protein mevalonate and sterol-biosynthesis module. Imetelstat increased 11 of 12 proteins, resulting in a 1.53-fold module increase (95% CI, 1.41-1.66, paired p = 4.5×10⁻⁴). Bafilomycin alone increased the same module 1.69-fold (Holm-adjusted p = 0.0022), whereas the combination produced little further increase (1.10-fold, p = 0.215, interaction Holm-adjusted p = 0.041). Metabolomics also showed a 2.3-fold increase in a putatively annotated sterol intermediate after imetelstat treatment. These findings separate the acute sterol-homeostatic response from the lysosomal-acidification-dependent accumulation of highly unsaturated phospholipids and triglycerides associated with imetelstat-induced ferroptosis.
We next tested whether the sterol response was adaptive. In our published genome-wide CRISPR/Cas9 screen in NB4 cells, SQLE- and FDFT1-targeting guides were depleted during prolonged imetelstat treatment. Together with their acute induction, these findings identify SQLE and FDFT1 as adaptive survival dependencies during treatment. Exploratory re-analysis of published baseline RNA-seq from pretreatment samples from 30 patients with AML showed enrichment of a broad SREBF1 target signature in poor responders to imetelstat (expression-matched p = 0.0099, Holm-adjusted p = 0.040). We therefore tested whether this response could be targeted pharmacologically. Fatostatin, an inhibitor of SREBP activation, synergised with imetelstat in NB4 and MOLM13 cells, reaching zero-interaction-potency synergy scores of 12.43 and 11.24, respectively. Validation in additional AML lines and with orthogonal sterol-pathway inhibitors is ongoing.
In summary, imetelstat induces lysosomal-acidification-dependent redistribution of highly unsaturated lipids associated with ferroptosis and stimulates a distinct sterol-homeostatic response that supports AML cell survival. These mechanistic insights identify sterol metabolism as a targetable adaptive vulnerability and support further evaluation of imetelstat combinations in AML.
DISCLOSURES
Claudia Bruedigam, PhD: No relevant conflicts of interest to declare.